72 results about "Tryptamine Receptors" patented technology

Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R<1>, R<2>, R<3>, R<4>, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.

A pyrrolesulfonamide derivative having the following formula (I):wherein the ring P represented byis a pyrrole ring having the following structure:wherein R represents alkyl, cycloalkyl, cycloalkyl-alkyl or aralkyl; the dashed line indicates the presence or absence of a bond; and, when the bond is present, Z2 is not present and Z1 represents H but, when the bond is absent, Z1 represents H and Z2 represents OH or Z1 and Z2 are combined together to represent O or a group NOR1, in which R1 represents H, or alkyl, aralkyl or aryl; l stands for 0 or 1; A represents alkylene, alkenylene or alkynylene; and Y represents a groupin which W represents CH, C═ or N; m stands for 0 or 1 when W is CH or N, or m stands for 1 when W is C═; B represents a specific divalent group; E1 and E2 each independently represents H or lower alkyl; and D represents an aromatic hydrocarbon group or heterocyclic group. The compound (I) has strong serotonin-2 receptor antagonistic action and low toxicity and less side effects, and is useful as a therapeutic for circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturbances.

The present invention relates to the application of aporphi compounds in the preparation of serotonin 2c receptor agonists. Apor phen compounds include compounds represented by general formula M, their isomers and pharmaceutically acceptable salts or Hydrate: where, R 1 , R 2 , R 3 independently selected from hydrogen, C 1 -C 8 Alkyl, C 2 -C 10 Alkynyl, C 2 -C 10 alkenyl, halogen, C 1 -C 8 Haloalkyl, cyano, nitro, aryl, hydroxyl, carboxyl, C 1 -C 8 alkoxy, alkoxyacyl, oxime, amino, amido, acyloxy, acyl, sulfonyl, sulfonylamino, urea, thiourea, or carbamoyl, and R 1 is a group other than hydroxyl; and R 1 When it is methoxy, R 2 , R 3 Cannot be hydroxyl and hydrogen respectively.

The invention relates to a 5-hydroxytryptamine receptor agonist, a preparing method thereof and uses of the receptor agonist, particularly (3a[alpha],4[beta],7[beta],7a[alpha])-hexahydro-2-[4[4-(2-pyrimidinyl)-1-(piperazinyl)]-butyl]-4,7-methylene-1H-isoindole-1,3(2H)-dione citrate monohydrate, a preparing method thereof and uses of the monohydrate. The molecular formula of the monohydrate is C<21>H<29>N5O2.C6H8O<7>.H2O. The monohydrate has advantages of high stability and good solubility, thus facilitating product quality control, increasing dissolution rates of preparations, and facilitating medicine absorption and utilization. The monohydrate can be prepared into various dosage forms conveniently, and is convenient to process, store and convey. The preparing method has advantages of few steps, simple and convenient operation, a high product yield, high purity, and the like and is particularly suitable for industrial application.